Format

Send to

Choose Destination
J Clin Oncol. 2019 Apr 2:JCO1801994. doi: 10.1200/JCO.18.01994. [Epub ahead of print]

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

Author information

1
1 Washington University School of Medicine, St Louis, MO.
2
2 National Cancer Institute, National Institutes of Health, Bethesda, MD.
3
3 Duke University, Durham, NC.
4
4 Cleveland Clinic, Cleveland, OH.
5
5 Mayo Clinic, Rochester, MN.
6
6 MedStar Georgetown University Hospital, Washington, DC.
7
7 University of Rochester, Rochester, NY.
8
8 The Ohio State University Comprehensive Cancer Center, Columbus, OH.
9
9 Massachusetts General Hospital Cancer Center, Boston, MA.
10
10 Vanderbilt University Medical Center, Nashville, TN.
11
11 Northwestern University, Chicago, IL.
12
12 University of Wisconsin, Madison, WI.
13
13 Univeristy of Washington, Seattle, WA.
14
14 Cornell University Medical College, New York, NY.
15
15 Fox Chase Cancer Center, Philadelphia, PA.
16
16 University of North Carolina, Chapel Hill, NC.
17
17 Memorial Sloan Kettering Cancer Center, New York, NY.

Abstract

PURPOSE:

Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as frontline therapy for diffuse large B-cell lymphoma.

PATIENTS AND METHODS:

Patients received six cycles of DA-EPOCH-R or R-CHOP. The primary objective was progression-free survival (PFS); secondary clinical objectives included response rate, overall survival (OS), and safety.

RESULTS:

Between 2005 and 2013, 524 patients were registered; 491 eligible patients were included in the final analysis. Most patients (74%) had stage III or IV disease; International Prognostic Index (IPI) risk groups included 26% IPI 0 to 1, 37% IPI 2, 25% IPI 3, and 12% IPI 4 to 5. At a median follow-up of 5 years, PFS was not statistically different between the arms (hazard ratio, 0.93; 95% CI, 0.68 to 1.27; P = .65), with a 2-year PFS rate of 78.9% (95% CI, 73.8% to 84.2%) for DA-EPOCH-R and 75.5% (95% CI, 70.2% to 81.1%) for R-CHOP. OS was not different (hazard ratio, 1.09; 95% CI, 0.75 to 1.59; P = .64), with a 2-year OS rate of 86.5% (95% CI, 82.3% to 91%) for DA-EPOCH-R and 85.7% (95% CI, 81.4% to 90.2%) for R-CHOP. Grade 3 and 4 adverse events were more common ( P < .001) in the DA-EPOCH-R arm than the R-CHOP arm, including infection (16.9% v 10.7%, respectively), febrile neutropenia (35.0% v 17.7%, respectively), mucositis (8.4% v 2.1%, respectively), and neuropathy (18.6% v 3.3%, respectively). Five treatment-related deaths (2.1%) occurred in each arm.

CONCLUSION:

In the 50303 study population, the more intensive, infusional DA-EPOCH-R was more toxic and did not improve PFS or OS compared with R-CHOP. The more favorable results with R-CHOP compared with historical controls suggest a potential patient selection bias and may preclude generalizability of results to specific risk subgroups.

PMID:
30939090
DOI:
10.1200/JCO.18.01994

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center